Search Results - "DePrimo, S."

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study by Philipp, S., Menter, A., Nikkels, A.F., Barber, K., Landells, I., Eichenfield, L.F., Song, M., Randazzo, B., Li, S., Hsu, M.‐C., Zhu, Y., DePrimo, S., Paller, A.S.

“…Summary Background Limited options are available for treatment of paediatric psoriasis. Objectives To evaluate the efficacy and safety of ustekinumab in…”
Get full text

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure by George, S, Blay, J.Y, Casali, P.G, Le Cesne, A, Stephenson, P, DePrimo, S.E, Harmon, C.S, Law, C.N.J, Morgan, J.A, Ray-Coquard, I, Tassell, V, Cohen, D.P, Demetri, G.D

“…Abstract Aims To assess the antitumour activity, safety, pharmacokinetics and pharmacodynamics of continuous daily sunitinib dosing in patients with…”
Get full text

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib by DePrimo, SE, Bello, C

“…Conventional methods to assess the clinical activity of new agents that target specific biological pathways involved in tumour pathology may not provide…”
Get full text

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours by Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V

“…Background: Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict…”
Get full text

Regulation of p53 expression by the RAS-MAP kinase pathway by AGARWAL, Munna L, RAMANA, Chilakamarti V, HAMILTON, Mark, TAYLOR, William R, DEPRIMO, Samuel E, BEAN, Lora J. H, AGARWAL, Archana, AGARWAL, Mukesh K, WOLFMAN, Alan, STARK, George R

“…Activation of MAP kinase leads to the activation of p53-dependent pathways, and vice-versa. Although the amount of p53 protein increases in response to MAP…”
Get full text

Mechanisms of G2 arrest in response to overexpression of p53 by Taylor, W R, DePrimo, S E, Agarwal, A, Agarwal, M L, Schönthal, A H, Katula, K S, Stark, G R

“…Overexpression of p53 causes G2 arrest, attributable in part to the loss of CDC2 activity. Transcription of cdc2 and cyclin B1, determined using reporter…”
Get full text

451 Association between HLA-Cw6 status and response to guselkumab in patients with moderate to severe plaque psoriasis by Liu, X., DePrimo, S., Chen, Y., Li, S., Munoz-Elias, E.

Get full text

Human placental alkaline phosphatase as a histochemical marker of gene expression in transgenic mice by DEPRIMO, S. E, STAMBROOK, P. J, STRINGER, J. R

“…The human placental alkaline phosphatase (PLAP) gene was analysed for its utility as a histochemically detectable reporter gene in transgenic mice. A reporter…”
Get full text

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer by FAIVRE, Sandrine, DELBALDO, Catherine, ARMAND, Jean-Pierre, SCIGALLA, Paul, RAYMOND, Eric, VERA, Karina, ROBERT, Caroline, LOZAHIC, Stéphanie, LASSAU, Nathalie, BELLO, Carlo, DEPRIMO, Samuel, BREGA, Nicoletta, MASSIMINI, Giorgio

“…To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and…”
Get full text

Prevention of prostate cancer by DePrimo, S E, Shinghal, R, Vidanes, G, Brooks, J D

“…Strategies for reducing the occurrence of prostate cancers will be critical in limiting the morbidity and mortality of this disease. The long latency period of…”
Get more information

Use of human placental alkaline phosphatase transgenes to detect somatic mutation in mice in situ by DePrimo, S E, Cao, J, Hersh, M N, Stringer, J R

“…Methods for in situ detection of cells that have suffered a specific mutation would be valuable for understanding somatic genetic mosaicism, a phenomenon that…”
Get full text

Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors by Zurita, A. J., Heymach, J., Khajavi, M., Tye, L., Huang, X., Kulke, M., Lenz, H., Meropol, N. J., Carley, W., DePrimo, S. E., Harmon, C. S.

“…Abstract only…”
Get full text

Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM) by DePrimo, S., Wu, B., Huang, S., Bautista, R., Cancilla, B., Vysotskaia, V., De Groot, J., Prados, M., Buller, R., Wen, P.

“…Abstract only 2049 Background: XL184 is an oral inhibitor of MET, RET, KIT, and VEGFR-2 with potent antitumor effects in preclinical models of GBM. Clinically,…”
Get full text

Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters by DePrimo, S. E., Cheng, A., Lanzalone, S., Lechuga, M. J., Harmon, C. S., Lin, X., Raymond, E., Faivre, S. J.

“…Abstract only…”
Get full text

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis by George, S., Blay, J. Y., Casali, P. G., Le Cesne, A., DePrimo, S. E., Harmon, C. S., Law, C. N., Tassell, V., Baum, C. M., Demetri, G. D.

“…Abstract only…”
Get full text

Cell cycle dependence of radiation-induced homologous recombination in cultured monkey cells by Cao, J, DePrimo, S E, Stringer, J R

“…A lacZ transgene recombination system that reports homologous recombination events involving duplicated lacZ segments was used to study recombination in monkey…”
Get more information

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma by MOTZER, Robert J, MICHAELSON, M. Dror, LI, Jim Z, BELLO, Carlo L, THEUER, Charles P, GEORGE, Daniel J, RINI, Brian I, REDMAN, Bruce G, HUDES, Gary R, WILDING, George, FIGLIN, Robert A, GINSBERG, Michelle S, KIM, Sindy T, BAUM, Charles M, DEPRIMO, Samuel E

“…Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression of pro-angiogenic growth…”
Get full text

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST by Blackstein, M., Huang, X., Demetri, G. D., Casali, P. G., Garrett, C. R., Schöffski, P., Shah, M. H., Verweij, J., Baum, C. M., DePrimo, S. E.

“…Abstract only 10007 Background: SU is an oral, multitargeted tyrosine kinase inhibitor of KIT, PDGFRs, VEGFRs, RET and FLT3, approved multinationally for the…”
Get full text

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer by Deprimo, S. E., Friece, C., Huang, X., Smeraglia, J., Sherman, L., Collier, M., Baum, C., Elias, A. D., Burstein, H. J., Miller, K. D.

“…Abstract only 578 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that…”
Get full text

Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3 by Bello, C., Deprimo, S. E., Friece, C., Smeraglia, J., Sherman, L., Tye, L., Baum, C., Meropol, N. J., Lenz, H., Kulke, M. H.

“…Abstract only 4045 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that…”
Get full text